Although the CAR T cells targeted both types of AML cells, the survival rate of FLT3 mut+ AML cells was lower than that of FLT3 mut− AML cells (p < 0.0001) (Fig. 2F), indicating that FLT3scFv/NKG2D-CAR T cells eradicated more FLT3 mut+ AML cells than FLT3 mut− AML cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.